Emmaus Life Sciences Reports Delayed Filing of Annual Report

Provided By PR Newswire

Last update: Apr 15, 2024

TORRANCE, Calif., April 15, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, reported today that the filing of its Annual Report on Form 10-K for the year ended December 31, 2023 will be delayed.